1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of mGluR2 receptors
AssigneeJanssen Pharmaceutica NV
InventorJosé Maria Cid-Núñez
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel 1,2,4-triazolo[4,3-a]pyridine compounds as positive allosteric modulators (PAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which mGluR2 subtype of metabotropic receptors is involved.
Claims8
A method of treating a subject having a central nervous system disorder selected from the group consisting of anxiety disorders, schizophrenia, schizoaffective disorder, schizophreniform disorder, personality disorders, substance abuse-related disorders, mood disorders, migraine, epilepsy, convulsive disorders and neurodegeneration comprising administering to the subject in need of treatment for said central nervous system disorder with a therapeutically effective amount of a compound of Formula (I)
- or a stereochemically isomeric form thereof, wherein
- R1 is selected from C1-6alkyl, (C3-8cycloalkyl)C1-3alkyl, and (C1-3alkyloxy)C1-3alkyl;
- or a pharmaceutically acceptable salt thereof.
A method of treating a subject having a central nervous system disorder selected from the group consisting of schizophrenia, generalized anxiety disorder, bipolar disorder (I or II), migraine, behavioral and psychological symptoms of dementia, epilepsy or convulsive disorders, panic disorder, mixed anxiety and depression, and agoraphobia comprising administering to said subject a therapeutically effective amount of
- (a) a compound of Formula (I)
- or a stereochemically isomeric form thereof, wherein
- R1 is selected from C1-6alkyl, (C3-8cycloalkyl)C1-3alkyl, and (C1-3alkyloxy)C1-3alkyl;
- or a pharmaceutically acceptable salt thereof;
- and
- (b) an mGluR2 orthosteric agonist,
- for simultaneous, separate or sequential administration.
Dependencies are inferred from the claim text.